Market Overview

Stemline Therapeutics Present Clinical Trial Results of Synthetic Peptide Vaccine for Brain Cancer at SNO Annual Meeting

Share:

Stemline Therapeutics (Nasdaq: STML) announced today that clinical trial results of a synthetic peptide vaccine for brain cancer, now being developed as SL-701, will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco, California on November 21-24, 2013. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells (CSCs).

The synthetic peptide vaccine developed by the University of Pittsburgh has previously demonstrated single-agent clinical efficacy, including complete responses (CRs), in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme (GBM). Based on these results, Stemline, who licensed patent rights relating to the Pitt vaccine from the University of Pittsburgh, is planning registration-directed programs in both adults and children with HGG.

According to a research abstract published on the SNO meeting website, University of Pittsburgh investigators will report on the safety and immunological responses achieved with the Pitt vaccine in an additional indication, adults with newly diagnosed or recurrent

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (STML)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Slideshow: iPhone 6 Price Hike, Huge PS4 Sales And More From The Third Week Of November

The Cash Store Adopts New By-Law